The lack of mutations found in IGF proteins in cancer may hint that INSR/IGF1R signalling is not a key driver in many tumours, and together with cross talk between pathways, this could explain the lack of efficacy seen in clinical trials using several different types of IGF1R‐targeted agent. The gene discussed is IGF1R; the disease is cancer.